Clinical trial · no report yet · Phase 3
NCT05870319
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
- NCT05870319 ↗
- Active not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 | |
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SKB264; Pemetrexed; Carboplatin; Cisplatin
- Arms
- SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle; · Experimental
- pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo · Active comparator
- Enrollment
- 376
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Jun 26, 2023
- Primary completion
- Jul 11, 2024
- Results posted
- No
- Registry record
- NCT05870319 · updated May 8, 2026
Publications
linked from the registry- Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026 Jan 1;394(1):13-26. doi: 10.1056/NEJMoa2512071. Epub 2025 Oct 19. PubMed 41124220